REGN vs TLSIW
Regeneron Pharmaceuticals Inc (REGN) versus TriSalus Life Sciences Inc. (TLSIW) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
TriSalus Life Sciences Inc. (TLSIW) common stock listed on NASDAQ.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
TLSIW does not have a complete income-statement cache yet.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. TLSIW currently screens at market cap $0.
Not investment advice. Open the REGN and TLSIW stock pages for the full models.
Not investment advice.